MenQuadfi

Land: Europäische Union

Sprache: Finnisch

Quelle: EMA (European Medicines Agency)

Wirkstoff:

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid

Verfügbar ab:

Sanofi Pasteur

ATC-Code:

J07AH08

INN (Internationale Bezeichnung):

meningococcal group A, C, W-135 and Y conjugate vaccine

Therapiegruppe:

rokotteet

Therapiebereich:

Meningiitti, meningokokki

Anwendungsgebiete:

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.

Produktbesonderheiten:

Revision: 8

Berechtigungsstatus:

valtuutettu

Berechtigungsdatum:

2020-11-18

Gebrauchsinformation

504 GATEWAY TIME-OUT

Fachinformation

504 GATEWAY TIME-OUT